Holocene Advisors LP Sells 2,706,169 Shares of Boston Scientific Corporation $BSX

Holocene Advisors LP decreased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 47.8% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 2,950,865 shares of the medical equipment provider’s stock after selling 2,706,169 shares during the period. Holocene Advisors LP’s holdings in Boston Scientific were worth $288,093,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Steph & Co. bought a new stake in Boston Scientific during the 3rd quarter worth approximately $25,000. Financial Consulate Inc. bought a new position in Boston Scientific in the 3rd quarter valued at $25,000. Murphy & Mullick Capital Management Corp boosted its stake in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC acquired a new position in Boston Scientific in the second quarter worth $26,000. Finally, United Community Bank grew its holdings in shares of Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Boston Scientific Trading Up 0.9%

Shares of BSX opened at $69.15 on Monday. The stock’s fifty day simple moving average is $82.47 and its 200-day simple moving average is $93.21. The firm has a market capitalization of $102.61 billion, a PE ratio of 35.64, a price-to-earnings-growth ratio of 0.97 and a beta of 0.69. Boston Scientific Corporation has a 12-month low of $67.56 and a 12-month high of $109.50. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company’s revenue was up 15.9% on a year-over-year basis. During the same period last year, the company earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of research reports. UBS Group lowered their target price on Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. Weiss Ratings lowered shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. Morgan Stanley lowered their price objective on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Robert W. Baird reduced their target price on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $108.00.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.